TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Broncus Holding Corp. ( (HK:2216) ) just unveiled an announcement.
Broncus Holding Corporation announced that its lung imaging processing software, BroncQCT®, has received approval for marketing in China from the Zhejiang Medical Products Administration. This software is designed to improve the efficiency of lung CT image examinations and supports clinical diagnosis and treatment, reinforcing Broncus’s position in the pulmonary disease treatment field. The software’s capabilities include pulmonary segmentation, quantitative data visualization, and three-dimensional reconstruction, which can aid in large-scale screenings and monitoring of pulmonary changes over time. This approval is a step towards offering a comprehensive solution for pulmonary health, integrating with Broncus’s existing interventional therapeutic products.
More about Broncus Holding Corp.
Broncus Holding Corporation is a company focused on precision interventional diagnostics and treatment for pulmonary diseases. It develops solutions that enhance clinical benefits, with products like lung imaging processing software and interventional therapeutic systems.
YTD Price Performance: 22.03%
Average Trading Volume: 1,366,105
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$373.4M
See more insights into 2216 stock on TipRanks’ Stock Analysis page.